Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 11, 2019 | September 12, 2019 |
| Twist Bioscience CorpTWST · Entity 3619 | Director | October 30, 2018 | October 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 11, 2019 · Filed September 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.00 · Expires 2029-09-11 | Direct | 40,000 |
Reported balance
After 2019-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-11 · Grant · Acquired 40,000 · Balance 40,000 F1: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one thirty-sixth of the shares on October 11, 2019 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one thirty-sixth of the shares on October 11, 2019 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Twist Bioscience Corp
Report date October 30, 2018 · Filed October 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2018-10-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2019 Filed Sep 12, 2019 15:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $39.00 | $0.00 |
DisclosureSEC source: 0000899243-19-023419 · doc4.xml · derivative · entry 1 Conley Paul A. · CIK 0001753671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires 2029-09-11 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one thirty-sixth of the shares on October 11, 2019 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.